Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00427557 · ClinicalTrials.gov registry record · Phase 2
Cellular Therapy With Cord Blood Cells
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT00427557: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00427557 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 31 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00427557, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if giving umbilical cord blood along with standard stem cells after high-dose chemotherapy will improve the response to a stem cell transplant. The safety of this treatment will also be studied.
Interventions
- DRUG Fludarabine
- DRUG Melphalan
- DRUG Rituximab
- PROCEDURE Umbilical Cord Blood
- OTHER Peripheral Blood Stem Cell Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2006-10 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00427557
The ClinicalTrials.gov registry entry for NCT00427557 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fludarabine is the first listed.
NCT00427557 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00427557 about?
NCT00427557 is a clinical study titled "Cellular Therapy With Cord Blood Cells". The goal of this clinical research study is to learn if giving umbilical cord blood along with standard stem cells after high-dose chemotherapy will improve the response to a stem cell transplant. The safety of this treatment will also be studied.
What is the current status of trial NCT00427557?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2006-10. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00427557?
The interventions under investigation include: Fludarabine (DRUG), Melphalan (DRUG), Rituximab (DRUG), Umbilical Cord Blood (PROCEDURE), Peripheral Blood Stem Cell Infusion (OTHER).
Who is sponsoring clinical trial NCT00427557?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.